Safety Study in Outpatient Japanese Children With ADHD

An Open-Label, Dose Titration Safety Study of Atomoxetine Hydrochloride in Outpatient Japanese Children With Attention-Deficit/Hyperactivity Disorder

Evaluate the safety and efficacy of atomoxetine in Japanese pediatric patients with ADHD.

Inclusion Criteria:

• Patients must be 6 - 18 years of age
• Patients must meet DSM-IV diagnostic criteria for ADHD
• Patient must be able to swallow capsules
• Patients must be of normal intelligence
• Laboratory results must show no significant abnormalities

Exclusion Criteria:

• Patients who weigh less than 15 kg or more than 75 kg at study entry
• Patients who have a documented history of bipolar disorder or any history of psychosis
• Patients taking any antipsychotic medication within 26 weeks of visit 1
• Patients with a severe history of allergies
• Patients taking methylphenidate